Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
NCT ID: NCT00642226
Last Updated: 2014-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
34 participants
INTERVENTIONAL
2006-11-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion
NCT00612261
Vitrectomy for Branch Retinal Vein Occlusion
NCT00685490
Radial Optic Neurotomy in Central Retinal Vein Occlusion : a Randomized Trial
NCT00379223
Pars Plana Vitrectomy With 25-gauge 20000 Cpm, Bevel-tip Cutter
NCT04404296
Vitrectomy Retinal Oxygenation
NCT01510691
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Grid Laser
Grid Laser
ETDRS Grid Laser
2
Vitrectomy in combination with 20 mg triamcinolone
Vitrectomy and 20 mg triamcinolone
Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Grid Laser
ETDRS Grid Laser
Vitrectomy and 20 mg triamcinolone
Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Best Corrected Visual Acuity of ≤ 20/40 on ETDRS chart
* Duration no shorter than 3 months
* Duration no longer than 12 months
Exclusion Criteria
* Blod in vitreous cavity
* Previous fundus laser treatment
* BRVO with over 180˚ of ischemia on FA
* Age under 18
* Other eye condition which contribute to relevant loss of visual acuity
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helse Stavanger HF
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johan Seland, PhD
Role: STUDY_DIRECTOR
Helse Stavanger HF
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stavanger University Hospital, Department of Ophthalmology
Stavanger, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3.2006.1159
Identifier Type: OTHER
Identifier Source: secondary_id
14836
Identifier Type: OTHER
Identifier Source: secondary_id
3.2006.1159(REK)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.